(PDF) Characteristics and Outcomes of Patients With

Characteristics and Outcomes of Patients With Relapsed Follicular Lymphoma Following Retreatment With Second-Line Rituximab-Containing Chemotherapy

Hematological Oncology - United Kingdom

doi 10.1002/hon.67_2631

Full Text

Abstract

Available in full text

Categories

Cancer Research

Date

June 1, 2019

Authors

Publisher

Wiley

Related search

Characteristics and Outcomes of Relapsed Follicular Lymphoma After Autologous Stem Cell Transplantation in the Rituximab Era

Hematological Oncology

Cancer Research

English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer Research

English

M7‐FLIPI Is Not Prognostic in Follicular Lymphoma Patients With First‐line Rituximab Chemo‐free Therapy

British Journal of Haematology

English

Management of Patients With Follicular Lymphoma Treated First Line With Obinutuzumab

Asia-Pacific Journal of Clinical Oncology

English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

English

A Retrospective Study on the Management of Patients With Rituximab Refractory Follicular Lymphoma

British Journal of Haematology

English

P109 Combined Chemotherapy Versus Topotecan Monotherapy as Second-Line Treatment for Patients With Sensitive Relapsed SCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Long-Term Follow-Up After Localized Radiotherapy in Patients With Transformed B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy

Hematological Oncology

Cancer Research

English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology

English